anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A readily obtainable powder cosmetic in a thin shape having stable qualities, readily obtained by blending a powder cosmetic base with a solvent and directly spraying the blend upon a container, a middle plate, etc. CONSTITUTION:A powder cosmetic base capable of being processed into powder cosmetic such as foundation, toilet powder, eye shadow, rouge, etc., is blended with a volatile solvent (e.g. water, ethyl alcohol, hexane, flon, etc.) in fixed amounts and dispersed to give a homogenous mixture. Then, the blend is sprayed by a spray gun, etc., from a spray nozzle, packed into a cosmetic retainer such as a container, middle plate, lamellar retainer, etc., directly, readily and uniformly and solidified to give a powder cosmetic. EFFECT:A powder cosmetic molded into a thin shape is readily obtained, convenient for carrying and light. A product having improved setting properties with other cosmetics and a product having shapes and thickness corresponding to needs can be provided.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a radix stephaniae tetrandrae and radix astragali decoction, wherein the raw materials of active ingredients comprise: 12 parts by weight of radix stephaniae tetrandrae, 15 parts by weight of radix astragali, 6 parts by weight of licorice, and 9 parts by weight of bighead atractylodes rhizome. The production process of the integrated new formulation of radix stephaniae tetrandrae and radix astragali decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of radix stephaniae tetrandrae and radix astragali decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of radix stephaniae tetrandrae and radix astragali decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of radix stephaniae tetrandrae and radix astragali decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
Currently, therapeutic options for severely brain-injured patients with disorders of consciousness (DOC), including patients in unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS), are limited and still need to be improved to influence long-term outcomes. Non-invasive brain stimulations (NIBS) techniques have recently shown promising results in DOC. Notably, transcranial direct current stimulation (tDCS) applied over the left dorsolateral prefrontal cortex has proved to be effective in improving signs of consciousness in about 50% of patients in MCS either after a single stimulation or after repeated sessions. However, brain mechanisms underlying tDCS effects remain poorly understood.In the present protocol, the investigators will assess the effects of prefrontal tDCS on neurophysiological (i.e., electroencephalography - EEG - primary outcome) and behavioral (secondary outcome) measures in severely brain-injured patients with DOC in a double-blind sham-controlled design. One anodal and one sham tDCS will be delivered in a randomized order in chronic (\>28 days post-onset) severely brain-damaged patients. The stimulation will have an intensity of 2 mA and will last 20 minutes. The anode will be placed on the left dorsolateral prefrontal cortex and the cathode on the right supraorbital region. Ten minutes of high-density EEG will be recorded using a 256-channel saline electrode net (Electrical Geodesics) directly before and after each tDCS session. Behavioral assessments will be performed using the Coma Recovery Scale-Revised before and after each session by an investigator blinded to the treatment allocation.
PURPOSE:To obtain a hair dyeing agent composition for hair having excellent dyeability and cleaning resistance, comprising 4 cationic compound. CONSTITUTION:A hair dyeing agent composition for hair comprising 0.01-15.0wt.% cationic compound (e.g. stearyltrimethylammonium chloride) as an active ingredient. Further addition of 0.01-5wt.% silicone provides hair with smoothness. The hair dyeing agent composition shows more improved touch after use than a case of using only the cationic compound. The blending ratio of the cationic compound and the silicone is 1:1 to 1:8. This hair dyeing agent composition makes the most of characteristics of one-pack type hair dyeing agent, is processed into a type also useful as rinse after shampoo and is usable in a wide range as a hair cosmetic.
PURPOSE: A thixotropic pharmaceutical composition of gel/sol/gel is provided to rapidly change viscosity and enables accurate drug administration. CONSTITUTION: A thixotropic pharmaceutical composition is a drug delivery composition containing a pharmacologically active ingredient; liquid substrate, and 0.01%(w/v)-12%(w/v) of biocompatible tackifier. The balance viscosity is less than 4,000 cps. The biocompatible tackifier is agar, carrageenan, gellan gum, colloidalsilicondioxide or xantan gum. The composition additionally contains sweetner or perfume and organic acid. The sweetener is mannitol, maltitol, sorbitol, xylitol, sugar alcohol containing isomalt, aspartame, acesulfame, saccharin, or sucralose.
The invention relates to a probiotic for animal husbandry, containing a microbial complex consisting of Lastobacillus acidophilus NBIMCC 8242, Lactobacillus helveticus NBIMCC 8269, Lactobacillus delbrueckii subsp. bulgaricus NBIMCC 8244, Lactobacillus delbrueckii subsp. lactis NBIMCC 8250, Streptococcus thermophilus NBIMCC 8253, Enterococcus faecium NBIMCC 8270 in an amount of 1 x 10 9 cfu / g and plant substrate derived from sunflower seed flour containing crude protein from 25.0 to 30.0% by weight, carbohydrates from 8.0 up to 11.0%, fat from 0.3 to 0.6%, fiber from 8.0 to 15.0% and free amino acids from 39.0 to 40.0%, such as lysine, methionine, cysteine, threonine, leucine , methylcysteine, aspartic acid, serine, glutamic acid, glycine, alanine, valine, isoleucine, phenylalanine, histidine, arginine. The invention also relates to a method for preparing the probiotic, consisting of dissolving sunflower seed flour in water, enzymatic treatment with a proteolytic enzyme selected from the group of serine proteases and a cellulotic enzyme selected from cellulase, phytase, after cooling the mixture what follows is fermentation with starter culture of Lactobacillus acidophilus NBIMCC 8242, Lactobacillus helveticus NBIMCC 8269, Lastoballus delbrueckii subsp. bulgaricus NBIMCC 8244, Lactobacillus delbrueckii subsp. lactis NBIMCC 8250, Streptococcus thermophilus NBIMCC 8253, Enterococcus faecium NBIMCC 8270 and carrying out a fermentation process during which is applied neutralization of the organic acids accumulating during the process, and afterwards the enriched product is cooled and subjected to pulverization. The application of the probiotic in animal husbandry leads to an increase in live weight of the animals while providing healthy nutrition and breeding, suppressing the putrefactive processes in the intestine and helping to restore and maintain beneficial gut microflora, further having a beneficial effect on intestinal function. All bacterial strains involved are isolated from environmentally friendly natural sources and are not genetically modified. The method, according to the invention, provides a product with a high content of beneficial microorganisms, produces metabolic substrates, such as vitamins and short-chain fatty acids, increases the content of soluble peptides, which leads to the production of natural antioxidants, and not least improves the functional properties of the product.
A facility diagnoses AMD in a subject patient. The facility obtains one or more patient images for a subject patient, which depict at least one of the subject patient's eyes. The facility applies an image-based classifier to at least one of the patient images to obtain a first AMD risk score. The facility identifies the macular region of an eye depicted in the patient images, and applies a deep learning-based classifier to the identified macular region to obtain a second AMD risk score. The facility identifies lesions present in an eye depicted in the patient images, and applies a deep learning-based classifier to the identified lesions to obtain a third AMD risk score. The facility combines the first AMD risk score, second AMD risk score, and third AMD risk score to obtain a unified AMD risk score.
There have been several reports, published and unpublished, concerning nonspecific small-bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of enteric-coated thiazides with potassium salts. These lesions may occur with enteric-coated potassium tablets alone or when they are used with nonenteric-coated thiazides, or certain other oral diuretics. These small-bowel lesions have caused obstruction, hemorrhage, and perforation. Surgery was frequently required and deaths have occurred. Based on a large survey of physicians and hospitals, both United States and foreign, the incidence of these lesions is low, and a causal relationship in man has not been definitely established. Available information tends to implicate enteric-coated potassium salts, although lesions of this type also occur spontaneously. Therefore, coated potassium-containing formulations should be administered only when indicated, and should be discontinued immediately if abdominal pain, distention, nausea, vomiting, or gastrointestinal bleeding occur. Large doses may cause hyperkalemia and alkalosis, especially in the presence of renal disease. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Do not exceed recommended dosage. Discontinue use if adverse reactions occur.

Should be used with caution by patients with low urinary output unless under the supervision of a physician. As with all liquids containing a high concentration of potassium, patients should be directed to dilute adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferably, to take each dose after meals to avoid saline laxative effect.
Small-cell lung cancer accounts for 13 to 15% of all lung cancer and more than 60 to 70% of patients present with extensive disease (ED). Although etoposide plus cisplatin (EP) regimen has been the mainstay of ED-SCLC treatment, median overall survival is about 9 months, with 5 to 10% surviving two years and only 1% of patients achieving a long-term disease-free survival. To improve this outcome further, various attempts have been made, which included dose intensification with stem cell supports, maintenance therapy, and also searches for a better chemotherapy regimen.

Significant anticarcinogenic effects of green tea extract on various organs, such as skin, stomach, duodenum, colon, liver, pancreas, and lung in rodent models have been confirmed. Recent scientific investigations have identified the active chemical compounds in green tea designated tea polyphenols or catechins. Epigallocatechin-3-gallate (EGCG) is the major catechin in tea.An investigation about the effects of EGCG on human SCLC cells revealed that EGCG had similar anti-tumor effects on drug-sensitive (H69) and drug-resistant (H69VP) SCLC cells. Thus, the investigators conduct this phase I trial, the objectives of this trial were to study the side effects and best dose of of EGCG in treating patients with small-cell lung cancer who achieved objective tumor response after first-line therapy.
The invention belongs to the technical field of cosmeceuticals and preparation methods thereof, and discloses a preparation for whitening and conditioning skin and a preparation method thereof. The preparation is prepared by combining conventional Chinese medicinal materials, leguminous plants and animal pancreas and mixing the materials according to a certain proportion. The compatibility of the raw materials is equivalent, and the function of mutual fusion of the raw materials is obviously enhanced, so that the effects of maintaining beauty and keeping young, locking water and keeping moisture, preventing and treating chap, cleaning and removing dirt, promoting blood circulation and dredging collaterals and eliminating edema are achieved. Under the effect of effective cooperation of various raw materials, the moisturizing and hydrating effects on the skin are remarkably promoted, so that the skin cell conditioning from inside to outside is completed, the skin metabolism is promoted, and the purposes of whitening and conditioning the skin are achieved. The preparation method has the advantages of simple operation process, less operation equipment, low requirement on operators and low cost. The method is safe and reliable, has no toxic or side effect, always retains the principles of maintaining ecological balance and protecting living environment in the process of collecting the medicinal materials, and is suitable for individuals of all ages.
CG-806 will be given orally in ascending doses in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphomas (escalation cohort), until the maximum tolerated dose or recommended dose is reached. Followed by up to 100 patients enrolled in the expansion cohort at the recommended dose.
PURPOSE:To obtain a pharmaceutical composition, containing calcitonins and an ethylenediaminetetraacetate and improved in stability. CONSTITUTION:A powdery or liquid pharmaceutical composition containing a remedial effective amount of calcitonins and an ethylenediaminetetraacetate in an amount of 0.005-50mug, preferably 0.02-0.5mug based on 1 I.U. calcitonins. Both ingredients are dissolved in water and the resultant aqueous solution is freeze-dried or an organic solvent is added to deposit the ingredients, which are then dried to afford the powdery composition capable of providing a powdery injection or powdery pharmaceutical for administration into the nasal cavity. Both ingredients are dissolved in water, an organic solvent (e.g. ethyl alcohol or propylene glycol) or a mixed solvent of water with the organic solvent to afford the liquid pharmaceutical composition capable of providing an injection, liquid administration agent into the nasal cavity or eye drop.
The invention discloses identification and therapeutic use of matrix metalloproteinase oligopeptides. The oligopeptides are used for making antibodies. The antibodies are used for diagnostic and treatment purposes of various diseases. In particular, the diseases may involve the mechanism of degradation of extracellular matrix by MMP's during cell proliferation cycle. Suppression of MMP activity seems to arrest tumor growth during cancer progression. MMP oligopeptides were used as vaccines to treat mice having murine melanoma B16FO induced tumor. There was a significant drop in tumor weight and size for the group of mice that were immunized with MMP oligopeptide.
Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
A suppressor of the expression of MCP-1 is provided that is excellent in safety and is widely applicable to, for example, foods. The suppressor of the expression of MCP-1 according to the present invention is characterized by containing auraptene. Auraptene is contained in citrus fruits such as Hassaku, Amanatsu, Natsumikan, and grapefruit. Since these citrus fruits have been eaten for a long time, the present invention has no problem in safety. Furthermore, even when added to, for example, foods, auraptene does not impair the flavor thereof because it is substantially tasteless and odorless. Since auraptene has a low calorific value, for example, an obese person or a diabetic patient can ingest it over a long period of time. Auraptene suppresses the expression of MCP-1 at a genetic level (see FIG.  1 ) and a protein level.
Although much progress has been made in chemotherapy or target therapy for advanced gastric cancer, the prognosis is still poor. It is necessary to screen biomarkers for early diagnosis and prognosis prediction. However, the prognostic value of LOX family in gastric cancer and the underlying molecular mechanisms for promoting the progression of gastric cancer remains unclear. Among five members of LOX family, LOXL1 was the unique independent prognostic risk factor. The nomogram established based on the expression of LOXL1 and other clinical parameters could predict the overall survival rate of gastric cancer. Knockdown (KD) of LOXL1 decreased cell proliferation and led to G1 phase arrest in gastric cells. According to GSEA analysis that LOXL1 was positively correlated with the WNT signaling pathway, in vitro experiment proved that LOXL1-KD reduced the phosphorylation level of β-catenin and the expression of the downstream G1 phase checkpoint CCND1. In conclusion, LOXL1 has been identified as a potential risk prognostic biomarker for gastric cancer by promoting gastric cancer proliferation via WNT/β-catenin/cyclinD1 pathway.
What is Oral Transmucosal Fentanyl Citrate (OTFC)?

  * OTFC is a prescription medicine that contains the medicine fentanyl. OTFC is a federally controlled substance (CII) because it is a strong opioid pain medicine that can be abused by people who abuse prescription medicines or street drugs.
  * OTFC is to be used only to treat breakthrough pain in adult patients with cancer (16 years of age and older) who are already using other opioid pain medicines for their constant (around-the-clock) cancer pain. OTFC is started only after you have been taking other opioid pain medicines and your body has gotten used to them (you are opioid tolerant). DO NOT USE OTFC if you are not opioid tolerant. Please talk with your doctor about whether or not you are opioid tolerant.
  * You must stay under your doctor’s care while taking OTFC.
  * OTFC must not be used for the treatment of short-term pain from injuries, surgery, or headaches, including migraines.
  * Prevent theft and misuse. Keep OTFC in a safe place to protect it from being stolen since it can be a target for people who abuse narcotic medicines or street drugs.
  * Never give OTFC to anyone else, even if they have the same symptoms you have. It may harm them and even cause death.
  * Selling or giving away this medicine is against the law.
BACKGROUND: Tranexamic acid is one component of a complex management algorithm for postpartum hemorrhage. In Japan, the 2010 obstetric hemorrhage management guidelines was revised in 2017, adding the recommendation for the administration of tranexamic acid for postpartum hemorrhage. This research aims to delineate the temporal trends in tranexamic acid administration in patients undergoing cesarean deliveries and to examine the impact of the obstetric hemorrhage management guidelines implementation.
METHODS: An interrupted time series analysis was conducted on data from patients who underwent cesarean deliveries from April 2012 to August 2021, sourced from Japan's nationwide health insurance claims database. We examined the trends of tranexamic acid usage and blood transfusion use before and after the implementation of the revised guidelines in 2017.
RESULTS: The study cohort comprised 91 166 cesarean deliveries. Prior to the guideline implementation, the rate of tranexamic acid usage decreased. Post-guidelines implementation, there was a statistically significant increase in the rate of tranexamic acid use, with a quarterly percentage change of 0.48% (95% confidence interval: 0.36 to 0.60; P < 0.001). The guidelines implementation in 2017 was not significantly associated with a change in the rate of transfusions.
CONCLUSIONS: This interrupted time series analysis demonstrated a significant increase in the rate of tranexamic acid administration following the implementation of the revised guidelines, reversing the previously observed downward trend. Our findings could reflect the impact of the revised guideline on the use of tranexamic acid for postpartum hemorrhage, but this did not translate to fewer blood transfusions.
PURPOSE:To obtain a herb tea stabilized and aged in drug action of a crude drug and capable of standing to long-term storage and simply usable by pulverizing each part of tree, grass, etc., having drug action and selecting and uniforming the resultant powder and blending the powder with a stabilizing and aging material in an adapted blend ratio to stabilize and age the powder. CONSTITUTION:Each part of tree, grass, etc., such as leaf, cellulose part, node or root suitably used according to each drug action is pulverized into size and shape adapted to optimum blend of the substrate with a stabilizing and aging material and selected and uniformed. Then the substrate is blended with the stabilizing and aging material in a blend ratio suitable for stabilization and aging. As the stabilizing and aging material, tea leaf or nucleic acid can be preferably used. Further, when far-infrared ray is irradiated as stabilization and aging, a far infrared ray radiating raw material may be applied to a throwing and drawing bag or incorporated into the bag. By the above-mentioned method, herb tea simply usable can be economically produced in large quantities.
ABSTRACT OF THE DISCLOSURE           A standardized preparation of intestinal origin is provided herein for the prophylaxis of intestinal disturbances, especially salmon-ella infections, in poultry.  At least two bacterial strains of normal alimentary tract (i.e. intestinal origin) bacterial species are anaero-bically cultivated either separately or together according to known methods, after which the cultivated bacteria are isolated from the nutri-ent medium and finished to a preparation, e.g., by lyophilization.  The cultivation may take place in the presence of epithelial cells from the alimentary tract, for example, the crop of a poult.  The bacterial strains used for the cultivation of the preparation are essentially those whose adhesion efficiency onto the epithelial cells of the alimentary tract of the poult has proved to be at least 10 bacteria per epithelial cell.  In this way improvements are provided in bacterial preparations useful in preventing infection  in young poultry.  In addition, chicks treated with such preparation display an improvement in health and faster growth.